Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes

Jasmin B. Kuemmerle-Deschner, E. Hachulla, R. Cartwright, P. N. Hawkins, T. A. Tran, B. Bader-Meunier, J. Hoyer, M. Gattorno, A. Gul, J. Smith, K. S. Leslie, S. Jiménez, S. Morell-Dubois, N. Davis, N. Patel, A. Widmer, R. Preiss, H. J. Lachmann

Research output: Contribution to journalArticlepeer-review

Abstract

Objective: Longer-term effects of prolonged selective interleukin-1β blockade with canakinumab were evaluated in the largest cohort of cryopyrin-associated periodic syndrome (CAPS) patients studied to date. Methods: Adult and paediatric CAPS patients (n=166, including canakinumab-naive and pretreated patients from previous studies) received canakinumab subcutaneously 150 mg or 2 mg/kg (≤40 kg) every 8 weeks for up to 2 years. Response and relapse was assessed using scores for disease activity, skin rash and C-reactive protein (CRP) and/or serum amyloid A (SAA) levels. Results: Complete response was achieved in 85 of 109 canakinumab-naive patients (78%; 79/85 patients within 8 days, and five patients between days 10 and 21). Of 141 patients with an available relapse assessment, 90% did not relapse, their CRP/SAA levels normalised (

Original languageEnglish
Pages (from-to)2095-2102
Number of pages8
JournalAnnals of the Rheumatic Diseases
Volume70
Issue number12
DOIs
Publication statusPublished - Dec 2011

ASJC Scopus subject areas

  • Rheumatology
  • Immunology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes'. Together they form a unique fingerprint.

Cite this